No matter whether you are a seasoned programmer or you simply want to take your first steps in writing code, Repl.it wants to help you get from idea to result as fast as possible — without complicated ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Rosalie Chan Every time Rosalie publishes a story, you’ll get an alert straight to your inbox!

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $12.82 / share. This is an increase of 10.52% from the prior estimate of $11.60 dated November 14, 2025. The ...

Replimune Group, Inc. (NASDAQ:REPL) stock plunged on Tuesday after a U.S. Food and Drug Administration (FDA) update. The clinical stage biotechnology company received an FDA Complete Response Letter ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Replimune Group REPL just hit that ...

Replimune Group announced that the U.S. Food and Drug Administration has accepted the resubmission of its Biologics License Application for RP1 in combination with nivolumab, targeting advanced ...

On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...